Zhou, J., Bai, X., Chen, Y., Liang, T., Wang, H., Sun, Y., Liang, X., Chu, Q., Wu, L., Zhou, C., Fang, J., Pan, Y., Cui, J., Huang, Z., Chen, Y., Zhou, C., Liu, X., Yang, Y., Li, N., Zhang, T. (2025). First-in-class PD-1/IL-2 bispecific antibody IBI363 in patients (Pts) with advanced immunotherapy-treated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.8509